THIRD AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 4th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
THIS THIRD AMENDMENT (this “Amendment”) is made and entered into as of July 5, 2011 by and between JAPAN TOBACCO INC., a Japanese corporation having its principal place of business at JT Building, 2-1 Toranomon, 2-chome, Minato-ku, Tokyo 105-8422, Japan (“JT”), and GILEAD SCIENCES, INC., a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, CA 94404, United States (“Gilead”). JT and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FOURTH AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 4th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
THIS FOURTH AMENDMENT (this “Amendment”) is made and entered into as of July 5, 2011 by and between JAPAN TOBACCO INC., a Japanese corporation having its principal place of business at JT Building, 2-1 Toranomon, 2-chome, Minato-ku, Tokyo 105-8422, Japan (“JT”), and GILEAD SCIENCES, INC., a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, CA 94404, United States (“Gilead”). JT and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 4th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
This Second Amendment to the License and Collaboration Agreement (this “Second Amendment”) is made as of July 1, 2011 (the “Second Amendment Effective Date”), by and among Gilead Sciences, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 333 Lakeside Drive, Foster City, California 94404 (“Gilead Parent”), Gilead Sciences Limited, a corporation existing under the laws of Ireland and wholly-owned subsidiary of Gilead Parent having its principal place of business at IDA Business & Technology Park, Carrigtohill, Co. Cork, Ireland (“Gilead Sub” and, collectively with Gilead Parent, “Gilead”) and Tibotec Pharmaceuticals, a company organized and existing under the laws of Ireland, having its principal place of business at Eastgate Village, Eastgate, Little Island, County Cork, Ireland (“Tibotec”). Each of Gilead and Tibotec is sometimes referred to individually herein as a “Party” and collectively as the “Parties.
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 4th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
This Amendment to License Agreement (“Amendment”) is made effective as of May 19. 2005 (the “Effective Date”) by and between Japan Tobacco Inc., a Japanese corporation having a principal place of business at JT Bldg. 2-1, Toranomon 2-chome, Minato-ku, Tokyo 105-8422, Japan (hereinafter, “JT”), and Gilead Sciences, Inc., a corporation having a principal place business at 333 Lakeside Drive, Foster City, California, U.S.A. (hereinafter, “GILEAD”).
SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 4th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
THIS SECOND AMENDMENT (the “Amendment”) is made and entered into as of May 17, 2010 (the “Amendment Execution Date”) by and between JAPAN TOBACCO INC., a Japanese corporation having its principal place of business at JT Building, 2-1 Toranomon, 2-chome, Minato-ku, Tokyo 105-8422, Japan (“JT”), and GILEAD SCIENCES, INC., a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, CA 94404, United States (“Gilead”). JT and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
